First of its kind research investigated the
impact of the changing weight-loss market on the Allurion
Program
Research included 172 healthcare professionals
(HCPs) and 1663 patients across 64 countries
Almost 90% of HCPs believed the Allurion
Program was an ideal first-line treatment to achieve >10% body
weight loss in a fast and sustainable way
Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to
ending obesity, today announced results of research that
highlighted the positive impact of the growing interest in
anti-obesity medications on Allurion Program awareness and
uptake.
The global market for anti-obesity medications – specifically of
GLP-1s (glucagon-like peptide-1 receptor agonists) – is expected to
reach $100 billion by 2030.1 Research has shown these products have
significantly altered the treatment landscape and drawn further
attention to the urgent need to tackle the obesity crisis.
In September 2023, Allurion conducted a survey of 172 healthcare
professionals to measure the potential impact of GLP-1 growth on
Allurion Program awareness among Allurion patients and healthcare
professionals (HCPs).
The results offer valuable insights into how GLP-1s have
influenced perceptions and attitudes towards medical weight-loss
generally, and the role the Allurion Program can play in helping
patients who are looking for a more holistic approach to weight
loss.
More specifically, the survey responses highlight a belief among
HCPs that the introduction of anti-obesity medications like GLP-1s
have had a positive impact on raising awareness of, and generating
interest in, other medical weight-loss treatment options, including
the Allurion Program.
Key findings included:
- Close to one-third of HCPs said patients had tried GLP-1s
before starting the Allurion Program. According to the survey
results, the 3 main factors influencing their decision to begin the
Allurion Program were their doctor’s recommendation; a preference
for avoiding the unwanted effects of weight-loss drugs; and the
ability of the Allurion Program to support rapid weight loss.
- 89% of HCPs believed the Allurion Program represented an ideal
first-line treatment to achieve at least 10% total body weight loss
in a fast and sustainable way
- HCPs offering GLP-1s experienced a 59% increase in patient
enquiries about other medically-led weight-loss treatments
- 45% of HCPs believed the new anti-obesity medications had
boosted awareness of, and interest in, the Allurion Program, and
34% of HCPs said they had no impact
Allurion also surveyed 1,663 Allurion Program patients from 64
markets. Results generally mirrored those of the HCP research.
Key findings included:
- Among the patients who had heard of GLP-1s (n=1014):
- 61% had increased awareness that diet and exercise alone were
not enough to treat obesity.
- 64% believed that learning about GLP-1s increased their
awareness of the availability of medical weight-loss
treatments.
- 50% agreed that learning about GLP-1s increased their awareness
of the Allurion Program. The remaining 50% said there was no impact
on their awareness of the Allurion Program.
- Among those patients who had tried GLP-1s (n=365):
- 85% had discontinued before starting the Allurion Program. The
two main reasons for discontinuation were not achieving their
weight-loss goals (36%) and negative side effects (32%).
- More than a quarter (n=449) of respondents had no intention of
trying weight-loss drugs in the future because they did not want to
take a drug or were worried about the potential negative health
impacts of weight-loss drugs.
Shantanu Gaur, CEO and founder of Allurion Technologies, said
GLP-1s had encouraged people living with obesity to seek
professional help.
“Over the last 12 months we have witnessed unprecedented growth
in the weight-loss category driven by the surge of interest in
GLP-1s,” he said. “This has promoted a better understanding of
weight management and evidence-based options in general, and we
believe this will ultimately benefit Allurion as well,” he
said.
“Unlike weight-loss drugs that require ingestion or injection,
Allurion offers a non-surgical, non-pharmaceutical solution
delivered as part of a comprehensive behavior change program that
generally results in rapid, safe and sustainable long-term weight
loss. We believe this is often preferred by both HCPs and patients
and, as a result, is an ideal first-line treatment in combatting
obesity.”
About the Market Research
This market research was conducted in September 2023 and
included 172 Allurion partner HCPs and 1663 Allurion Program
patients.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is
a weight-loss platform that combines the Allurion Gastric Balloon,
the world’s first and only swallowable, procedure-less gastric
balloon for weight loss, the Allurion Virtual Care Suite, including
the Allurion Mobile App for consumers, Allurion Insights for
healthcare providers featuring the Iris AI Platform, and the
Allurion Connected Scale. The Allurion Virtual Care Suite is also
available to providers separately from the Allurion Program to help
customize, monitor, and manage weight-loss therapy for patients
regardless of their treatment plan: gastric balloon, surgical,
medical or nutritional. The Allurion Gastric Balloon is an
investigational device in the United States. For more
information about Allurion and the Allurion Virtual Care Suite,
please visit www.allurion.com.
Forward-looking Statements
This press release may contain certain forward-looking
statements within the meaning of the U.S. federal and state
securities laws. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions and
include statements regarding Allurion’s expectations for, and
market acceptance of, the Allurion Program. They reflect the
current beliefs and assumptions of Allurion’s management based on
information currently available to them. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future results or developments to differ
materially from the forward-looking statements in this
communication, including but not limited to (i) the ability of
Allurion to obtain regulatory approval for and successfully
commercialize the Allurion Program, (ii) the results of clinical
data from its studies, (iii) the evolution of the markets in which
Allurion competes, (iv) the ability of Allurion to defend its
intellectual property and satisfy regulatory requirements, (v) the
impact of the COVID-19 pandemic on Allurion’s business, (vi)
Allurion’s expectations regarding its market opportunities and
(vii) the risk of economic downturns and a changing regulatory
landscape in the highly competitive industry in which Allurion
operates. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of the
proxy statement/prospectus contained in Allurion’s Registration
Statement on Form S-4 (333-271862), the company’s Form 8-K filed on
August 7, 2023 (as amended), and other documents filed by Allurion
from time to time with the U.S. Securities and Exchange Commission.
These filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Allurion assumes no obligation and does not intend
to update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Allurion
does not give any assurance that it will achieve its
expectations.
1 Bloomberg.com: Obesity Drugs Are a Potential $100 Billion
Opportunity by 2030, Goldman Sachs Analysts Say
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240105026245/en/
US Media Brian Ruby ICR (203) 682-8268
brian.ruby@icrinc.com Global Media Cedric Damour PR Manager
+33 7 84 21 02 20 cdamour@allurion.com Investor Contact Mike
Cavanaugh, Investor Relations ICR Westwicke (617) 877-9641
mike.cavanaugh@westwicke.com
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Allurion Technologies (NYSE:ALUR)
Historical Stock Chart
From Dec 2023 to Dec 2024
